Kyverna Therapeutics, Inc. (KYTX) Form 8-K — May 18, 2026

$KYTXForm 8-KItems 5.02, 8.01, 9.01Filed May 18, 2026, 8:00 AM ET0001193125-26-227920Original filing

Kyverna Therapeutics appointed Gregory Martini as Chief Financial Officer, effective May 18, 2026, succeeding Marc Grasso who will transition to a strategic advisor role. Martini joins from Ironwood Pharmaceuticals, where he served as CFO, bringing experience in capital allocation and investor relations for a commercial-stage biotech. Martini’s compensation package includes a $525,000 annual base salary, a 40% target performance bonus, and a $300,000 sign-on bonus. He also received an inducement grant of 325,000 stock options vesting over four years, exempt from shareholder approval under Nasdaq rules.

Key figures

Base salary: $525,000
Sign on bonus: $300,000
Vesting period years: 4
Inducement option shares: 325000
Performance bonus target: 40% of base salary

Price after filing

1 day: +1.9%7 days: +4.2%30 days: -7.3%

Close on the filing date to close N calendar days later (from $8.54). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $40.67/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.